We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · May 21, 2021

Efficacy and Safety of Biosimilar FYB201 vs Ranibizumab in Neovascular AMD

Ophthalmology

 

Additional Info

Ophthalmology
Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration
Ophthalmology 2021 May 03;[EPub Ahead of Print], FG Holz, P Oleksy, F Ricci, PK Kaiser, J Kiefer, S Schmitz-Valckenberg, COLUMBUS-AMD Study Group

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading